Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
present positive Phase 1 trial results on IMO-8400, a selective
inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate
for the treatment of autoimmune diseases, at the 13th Annual
Meeting of the Federation of Clinical Immunology Societies (FOCIS), June
27-30, 2013, in Boston, MA.
Details of the presentation are as follows:
|
|
|
|
|
|
|
Date:
|
|
|
|
Saturday, June 29, 2013
|
|
Time:
|
|
|
|
6:30-7:45pm ET
|
|
Location:
|
|
|
|
Commonwealth Hall, The Boston Seaport Hotel
|
|
Abstract Number:
|
|
|
|
S.85
|
|
Title:
|
|
|
|
Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like
receptors 7, 8 and 9
|
|
|
|
|
|
|
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates and
has a clinical development program in autoimmune diseases. Additionally,
Idera has a collaboration with Merck & Co. for the use of TLR-targeted
candidates as vaccine adjuvants for cancer, infectious diseases and
Alzheimer’s disease. For more information, visit http://www.iderapharma.com.
<div class="copyright">
Copyright Business Wire 2013
</div>